Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants

Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants

Abstract Co‐administration of clesacostat (acetyl‐CoA carboxylase inhibitor, PF‐05221304) and ervogastat (diacylglycerol O‐acyltransferase inhibitor, PF‐06865571) in laboratory models improved non‐alcoholic fatty liver disease (NAFLD)/non‐alcoholic steatohepatitis (NASH) end points and mitigated cle...

Full description

Bibliographic Details
Main Authors: Aarti Sawant‐Basak, Arthur J. Bergman, Jessica Mancuso, Sakambari Tripathy, James R. Gosset, Laure Mendes da Costa, William P. Esler, Roberto A. Calle
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13687

Internet

https://doi.org/10.1111/cts.13687

Similar Items